Next Generation Drugs: Acceleration Through Innovation

Scripp Business Insights, March 2002

The pharmaceutical industry is now immersed in a wave of technological innovation to help accelerate drug discovery and development. However, selecting the most beneficial technological systems to reduce discovery and development timelines involves due consideration of a company''s R&D focus, pipeline commitments, synergies to enhance R&D programmes, and analysis of risk and competition. Next Generation Drugs: Acceleration through innovation is a new management report examining the technological innovations that are being employed by the pharmaceutical majors to expedite discovery research and R&D. Key areas of review include genomics, proteomics, pharmacogenomics, bioinformatics, and cheminformatics in addition to other key enabling high technology discovery and development platforms. This new report also reviews how companies are accelerating discovery through strategic collaborations, enhancement of in-house expertise, and by focusing on specific diseases or small molecules to optimize their future business plans.

Customers who bought this item also bought

• Top 10 Drug Discovery Technologies – Strategic Analysis And Global Forecasts
• Overview of the European Drug Discovery Market
• Drug Discovery Technologies - Global Strategic Business Report
• Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs
• Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation
• Preclinical Models: Innovative Solutions to Accelerate Drug Discovery and Development
• The New Trends of Global Pharmaceutical Outsourcing: New Developments in Strategy, Market, Service and Technology
• Biomarkers - Advanced Technologies and Global Market (2009-2014)
• The New Trends of Drug Discovery Outsourcing in China and India 2012
• Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market